{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:49Z","timestamp":1740138529288,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently thioguanine is solely used as treatment for inflammatory bowel disease after azathioprine and\/or mercaptopurine failure. This study aimed to determine the safety, effectiveness, and 12-month drug survival of thioguanine in thiopurine-na\u00efve patients with inflammatory bowel disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was performed in thiopurine-na\u00efve patients with inflammatory bowel disease treated with thioguanine as first thiopurine derivate. Clinical effectiveness was defined as the continuation of thioguanine without the (re)initiation of concurrent biological therapy, systemic corticosteroids, or a surgical intervention. All adverse events were categorized by the Common Terminology Criteria for Adverse Events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 114 patients (male 39%, Crohn\u2019s disease 53%) were included with a median treatment duration of 25 months and a median thioguanine dosage of 20 mg\/d. Clinical effectiveness at 12 months was observed in 53% of patients, and 78% of these responding patients remained responsive until the end of follow-up. During the entire follow-up period, 26 patients were primary nonresponders, 8 had a secondary loss of response, and 11 patients were unable to cease therapy with systemic corticosteroids within 6 months and were therefore classified as nonresponders. After 12 months, thioguanine was still used by 86% of patients. Fifty (44%) patients developed adverse events (grade 1 or 2) and 9 (8%) patients ceased therapy due to the occurrence of adverse events. An infection was documented in 3 patients, none of them requiring hospitalization and pancytopenia occurred in 2 other patients. No signs of nodular regenerative hyperplasia or portal hypertension were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>At 12 months, first-line thioguanine therapy was clinically effective in 53% of thiopurine-na\u00efve inflammatory bowel disease patients with an acceptable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad197","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T12:48:36Z","timestamp":1693658916000},"page":"1492-1499","source":"Crossref","is-referenced-by-count":3,"title":["The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Na\u00efve Inflammatory Bowel Disease Patients"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-9146","authenticated-orcid":false,"given":"Femke","family":"Crouwel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed B","family":"Bayoumy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris J J","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job H C","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Rode Kruis hospital , Beverwijk , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J","family":"Boekema","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, M\u00e1xima Medical Centre , Veldhoven , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc J J","family":"Derijks","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, M\u00e1xima Medical Centre , Veldhoven , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybrand Y","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Slingeland Hospital , Doetinchem , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C","family":"van de Meeberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Slingeland Hospital , Doetinchem , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishfaq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Streekziekenhuis Koningin Beatrix , Winterswijk , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J C","family":"Buiter","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanne K","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"issue":"1","key":"2024090305512954300_CIT0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024090305512954300_CIT0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024090305512954300_CIT0003","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad022","article-title":"Mercaptopurine for the treatment of ulcerative colitis - a randomised placebo-controlled trial","author":"L\u00f6wenberg","year":"2023;17(7):1055-1065","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2024090305512954300_CIT0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"40","key":"2024090305512954300_CIT0005","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v22.i40.9012","article-title":"Efficacy of thioguanine treatment in inflammatory bowel disease: a systematic review","volume":"22","author":"Meijer","year":"2016","journal-title":"World J Gastroenterol."},{"issue":"9","key":"2024090305512954300_CIT0006","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FPC.0b013e328334338f","article-title":"Thiopurine pathway","volume":"20","author":"Zaza","year":"2010","journal-title":"Pharmacogenet Genomics."},{"issue":"1","key":"2024090305512954300_CIT0007","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12876-020-01441-6","article-title":"Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom","volume":"20","author":"Bayoumy","year":"2020","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"2024090305512954300_CIT0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.15280","article-title":"Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies","volume":"50","author":"Simsek","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024090305512954300_CIT0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00042737-200301000-00011","article-title":"6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment","volume":"15","author":"Derijks","year":"2003","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"6","key":"2024090305512954300_CIT0010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/ecco-jcc\/jjad013","article-title":"Thioguanine is effective as maintenance therapy for inflammatory bowel disease: a prospective multicentre registry study","volume":"17","author":"Simsek","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2024090305512954300_CIT0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut."},{"issue":"3","key":"2024090305512954300_CIT0012","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","article-title":"Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC","volume":"44","author":"Dervieux","year":"1998","journal-title":"Clin Chem."},{"issue":"11","key":"2024090305512954300_CIT0013","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/clinchem\/46.11.1728","article-title":"Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, \u201ctwo-color\/shared\u201d anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design","volume":"46","author":"Sch\u00fctz","year":"2000","journal-title":"Clin Chem."},{"issue":"4","key":"2024090305512954300_CIT0014","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn\u2019s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut."},{"issue":"6","key":"2024090305512954300_CIT0015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.17128","article-title":"Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease","volume":"56","author":"Rezazadeh Ardabili","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"2024090305512954300_CIT0016","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/MIB.0000000000001168","article-title":"Optimizing Thiopurine therapy in inflammatory bowel disease among 2 real-life intercept cohorts: effect of allopurinol comedication","volume":"23","author":"Meijer","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"25","key":"2024090305512954300_CIT0017","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","article-title":"Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease","volume":"21","author":"Moran","year":"2015","journal-title":"World J Gastroenterol."},{"issue":"12","key":"2024090305512954300_CIT0018","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","article-title":"Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2024090305512954300_CIT0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut."},{"issue":"5","key":"2024090305512954300_CIT0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2024090305512954300_CIT0021","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/apt.14571","article-title":"Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine\/mercaptopurine nonresponders (AAA Study)","volume":"47","author":"Friedman","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024090305512954300_CIT0022","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ibd.23021","article-title":"Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease","volume":"19","author":"Hoentjen","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2024090305512954300_CIT0023","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.dld.2018.02.001","article-title":"Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease","volume":"50","author":"Vasudevan","year":"2018","journal-title":"Dig Liver Dis."},{"issue":"4","key":"2024090305512954300_CIT0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.15402","article-title":"Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment","volume":"50","author":"Kreijne","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2024090305512954300_CIT0025","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1007\/s10620-021-07273-y","article-title":"Azathioprine with allopurinol is a promising first-line therapy for inflammatory bowel diseases","volume":"67","author":"van Liere","year":"2022","journal-title":"Dig Dis Sci."},{"key":"2024090305512954300_CIT0026","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.eclinm.2022.101332","article-title":"Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): an investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial","volume":"45","author":"Kiszka-Kanowitz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"11","key":"2024090305512954300_CIT0027","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.15730","article-title":"A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2024090305512954300_CIT0028","doi-asserted-by":"crossref","first-page":"e0212157","DOI":"10.1371\/journal.pone.0212157","article-title":"Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review","volume":"14","author":"Toksvang","year":"2019","journal-title":"PLoS One."},{"issue":"9","key":"2024090305512954300_CIT0029","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1097\/MIB.0000000000000869","article-title":"The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease","volume":"22","author":"van Asseldonk","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2024090305512954300_CIT0030","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ibd.20492","article-title":"Further experience with the use of 6-thioguanine in patients with Crohn\u2019s disease","volume":"14","author":"Ansari","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024090305512954300_CIT0031","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2005.11.049","article-title":"6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent","volume":"44","author":"Derijks","year":"2006","journal-title":"J Hepatol."},{"issue":"5","key":"2024090305512954300_CIT0032","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00365520701800266","article-title":"Histopathology of liver biopsies from a thiopurine-na\u00efve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia","volume":"43","author":"De Boer","year":"2008","journal-title":"Scand J Gastroenterol."},{"issue":"4","key":"2024090305512954300_CIT0033","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00004836-199008000-00023","article-title":"Nodular regenerative hyperplasia of the liver: retrospective survey in autopsy series","volume":"12","author":"Nakanuma","year":"1990","journal-title":"J Clin Gastroenterol."},{"issue":"5","key":"2024090305512954300_CIT0034","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.1840110512","article-title":"Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules","volume":"11","author":"Wanless","year":"1990","journal-title":"Hepatology."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad197\/51333950\/izad197.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad197\/58843751\/izad197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad197\/58843751\/izad197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T05:51:47Z","timestamp":1725342707000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/9\/1492\/7258971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,2]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad197","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2023,9,2]]}}}